First Trust Mid Cap Growth AlphaDEX Fund


Добавить в список отслеживания Добавить в список отслеживания
Добавить в портфель Добавить в портфель

Основные параметры

Цена последней сделки 70.62
Код ценной бумаги FNY
Полное наименование First Trust Mid Cap Growth AlphaDEX Fund
Объем 488390000000
Изм за день, % 0.01
Комиссия 0.70
Дата основания Apr 19. 2011
Ссылка ссылка
Тип актива Equity
Индекс Defined Mid Cap Growth Index
Регион North America
Средний P/E 30.39
Дивиденды 0.23
5 летняя доходность 171.70
3 летняя доходность 71.23
Годовая доходность 43.32
Бета 1.17

Топ эмитентов

Эмитент Доля, %
Darling Ingredients Inc. 0.8
Chewy 0.83
Fate Therapeutics 0.87
Enphase Energy, Inc. 0.79
Tenet Healthcare Corporation 0.83
Overstock.com, Inc. 0.91
Albemarle 0.87
II-VI Incorporated 0.85
Advanced Energy Industries, Inc. 0.89
Inspire Medical Systems, Inc. 0.82
Elastic N.V. 0.8
Entegris, Inc. 0.79
Antero Midstream Corporation 0.77

Описание First Trust Mid Cap Growth AlphaDEX Fund

This ETF is one of several products offering exposure to mid cap growth stocks, a corner of the domestic equity market that may feature a unique risk/return profile and be attractive in certain environments. Given the narrow focus, FNY might not be on the radar screens of those building a long-term, buy-and-hold portfolio; many investors will elect to achieve exposure to this slice of the market through more broadly-based equity ETFs that don't focus exclusively on a single style. FNY can, however, be useful to those building U.S. equity exposure piece by piece or for those looking to implement a tactical tilt towards this corner of the market. FNY stands apart from other options in the Mid Cap Growth ETFdb Category because of the unique methodology behind the underlying index. FNY is part of the AlphaDEX suite of products that seek to replicate "enhanced" indexes that rely on quant-based screens to determine component companies. This process aims to select the most promising stocks from the broader universe, which if successful would result in a product that outperforms indexes that simply own the market. As such, FNY blurs the lines between active and passive management; this indexed product essentially seeks to outperform cap-weighted benchmarks. For those who think the AlphaDEX methodology can generate excess returns over the long run, FNY might be a nice way to access this asset class. For those looking to keep costs down and happy to simply own the market; FNY probably doesn't have much appeal; this fund is considerably more expensive than alternatives such as VOT or IJK.